Clinical Trial Update: Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing rezafungin to caspofungin in candidemia and invasive candidiasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Fungal Infection
• Invasive Candidiasis
• Mycoses

Drugs mentioned

• Caspofungin (caspofungin)
• Rezafungin (rezafungin)

Snippet

Sponsor: Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Candidemia, Mycoses | Phase 3 | Status: COMPLETED | Results posted: 2023-01-06